Home

JOSEPH L HERRING

CIK 1229873 · CEO of Covance Drug Division · last filed 2026-03-09

JOSEPH L HERRING is a CEO of Covance Drug Division who has filed 57 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for HSIC, was dated Jun 30, 2026. Across all open-market trades the lifetime net is −$56.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.0M across reported positions. 16 SEC filings were submitted jointly with HENRY SCHEIN INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$7.01M

Companies

4

Total Filings

57

Lifetime Open-Market Net

-$56.74M

Filer Profile

Reported Address
210 CARNEGIE CENTER
PRINCETON, NJ 08540
Related Filers
HENRY SCHEIN INC — 16 joint filings, latest 2026-06-30
LABORATORY CORP OF AMERICA HOLDINGS — 4 joint filings, latest 2015-08-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
HSIC Director 32,281 $89.81 $2.90M $127.1K 14 2026-03-09
TMH Director 2,982 $51.36 $153.2K $0 4 2016-05-24
LH CEO of Covance Drug Division 12,110 $326.89 $3.96M -$4.49M 3 2015-08-04
COVANCE INC (CVD) Delisted Chairman and CEO 175,643 — — -$52.38M 34 2014-12-19

Recent Filings

57 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-30 HSIC Notice (144) −28,791 -$2.43M EDGAR
2026-03-09 HSIC Grant (A) +2,577 $0 EDGAR
2025-03-06 HSIC Grant (A) +2,844 $0 EDGAR
2024-03-05 HSIC Grant (A) +2,604 $0 EDGAR
2023-03-03 HSIC Grant (A) +2,250 $0 EDGAR
2022-03-18 HSIC Grant (A) +2,028 $0 EDGAR
2021-03-05 HSIC Grant (A) +2,790 $0 EDGAR
2020-03-05 HSIC Grant (A) +2,889 $0 EDGAR
2019-03-06 HSIC Grant (A) +2,972 $0 EDGAR
2018-03-06 HSIC Grant (A) +2,843 $0 EDGAR
Showing 1–10 of 57
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.